LOG IN 
Event Overview
Share
Send to colleagueMeeting Overview
Apply now to engage with experts in the field of pancreatic cancer by joining this highly interactive 1.5-day live meeting. Our multidisciplinary experts will provide a comprehensive update on the management of pancreatic cancer, focusing on recent developments for patients with resectable, unresectable, and metastatic pancreatic cancer as well as supportive care and adverse event management by using the following strategies:
- Didactic presentations
- Case-based presentations and clinical management discussions
- Quiz questions
- Q & A sessions
Date and Location
Friday and Saturday
28 – 29 September 2018
Room: Paris
Renaissance Wien
Linke Wienzeile/Ullmannstrasse 71
Vienna, Austria
Travel Grant Information
To apply for a travel grant, click on the Apply Now button.
Date/Time
28 – 29 September 2018
Location
Vienna, Austria
IME
Agenda coming soon!
-
Philip Agop Philip, MD, PhD, FRCPWayne State University and Karmanos Cancer Institute
Detroit, Michigan, United States -
Thomas Seufferlein, MD, PhD University of Ulm
Ulm, Germany -
Eric Van Cutsem, MD, PhDUniversity Hospitals Leuven
Leuven, Belgium
Chairs
*Additional faculty to be confirmed
This educational activity is designed for European gastroenterologists, surgical, radiation, and medical oncologists, and other healthcare providers involved in the management of patients with pancreatic cancer.
After successful completion of this educational activity, participants should be able to:
- Describe the genomic complexity and molecular heterogeneity of pancreatic cancer
- Identify multimodality treatment strategies for localized resectable, borderline, and unresectable pancreatic cancer
- Select the most appropriate therapeutic approach for metastatic pancreatic ductal adenocarcinoma based on patient and disease characteristics, both in the first-line setting and beyond
- Assess supportive care measures to ameliorate disease symptoms and treatment-related adverse events throughout the course of pancreatic cancer treatment
- Describe emerging treatment strategies in pancreatic cancer, including the role of immunotherapy
This educational activity is supported by grants from Celgene, ERYTECH, RAFAEL Pharmaceuticals, and Shire.
INDEPENDENT MEDICAL EDUCATION (IME)
This IME activity is organized by prIME Oncology. This activity provides content that is evidence-based, balanced, and free of commercial bias, with a primary objective to improve competence and performance of learners in order to improve patient care.
Provider
This activity is provided by prIME Oncology.
SUNSHINE ACT/EFPIA
prIME Oncology complies with all Sunshine Act reporting requirements as outlined by CMS and applicable manufacturers and with EFPIA Disclosure Code reporting requirements.
Disclosures
Disclosure of Relevant Financial Relationships
prIME Oncology assesses the relevant financial relationships of its instructors, planners, managers, and other individuals who are in a position to control the content of CME activities. Any potential conflicts of interest that are identified are thoroughly vetted by prIME Oncology for fairness, balance, and scientific objectivity of data, as well as patient care recommendations. prIME Oncology is committed to providing its learners with high-quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial entity.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Disclosure Regarding Unlabeled Use
This activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration or European Medicines Agency. Please refer to the official prescribing information for each product discussed for discussions of approved indications, contraindications, and warnings.